Clinical Trials Logo

Filter by:
  • Suspended  
  • Page [1] ·  Next »
NCT ID: NCT06264856 Suspended - Chest Trauma Clinical Trials

Bronchoscopy for Thoracic Trauma Patients

Start date: December 1, 2024
Phase: N/A
Study type: Interventional

The study aims to evaluate the effectiveness of bronchoscopic sputum suction in patients with severe thoracic illness-induced respiratory failure. The study will compare the outcomes of patients who receive bronchoscopic sputum suction versus blind negative pressure aspiration for sputum removal. The study will measure baseline data, postoperative blood gas conditions, and clinical parameters, such as time of invasive ventilation, total time of ventilation, hospital stay, weaning success rate, reintubation rate, ventilator-associated pneumonia incidence, and fatality rate. The study aims to determine whether bronchoscopy-assisted sputum removal is superior to blind negative pressure aspiration in improving patient outcomes.

NCT ID: NCT05355506 Suspended - Heart Failure Clinical Trials

The Development and Effectiveness of Heart Failure Self-Health Management Application

APP
Start date: July 1, 2019
Phase:
Study type: Observational [Patient Registry]

Aims: To develop a smartphone application and investigate its effectiveness on patients with heart failure after using the "heart failure self-health management application.".

NCT ID: NCT05202327 Suspended - Clinical trials for Attention-Deficit Hyperactivity Disorder (ADHD)

PDC-1421 Treatment in Adult Patients With ADHD

Start date: April 7, 2022
Phase: Phase 2
Study type: Interventional

Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective is to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.

NCT ID: NCT05006781 Suspended - Dementia Clinical Trials

The Dose Finding Study of DAOIB Added to tDCS for AD

Start date: January 2025
Phase: Phase 2
Study type: Interventional

This is a 26-week randomized, double-blind, placebo-controlled trial. We will enroll patients with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10 sessions in total) during the first 2 weeks of the study, and will also be allocated randomly to either of 4 treatment groups for 24 weeks: (1) Dose A group; (2) Dose B group; (3) Dose C group; (4) placebo group. We will assess the patients every 8 weeks during the treatment period (weeks 0, 10, 18, and 26). We hypothesize that augmentation with certain dose of DAOIB will yield better effect than tDCS alone in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.

NCT ID: NCT04520412 Suspended - Alzheimer Disease Clinical Trials

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

GREEN MEMORY
Start date: October 27, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.

NCT ID: NCT04515953 Suspended - Pain, Postoperative Clinical Trials

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)

Start date: October 15, 2020
Phase: Phase 1
Study type: Interventional

This study focused on ND-340 extended release injection suspension for patients undergoing total knee arthroplasty with a one-time nerve blockade to assess drug side effects, pharmacokinetics and the effect of pain relief after surgery.

NCT ID: NCT03848260 Suspended - Clinical trials for Paralytic Lagophthalmos

A Real-Time Magnetic Device Prototype for Temporary Management of Paralytic Lagophthalmos

Start date: May 1, 2025
Phase: N/A
Study type: Interventional

To develop a real-time wearable device based on the principle of magnetic force for temporary management of lagophthalmos, and evaluate its efficacy and safety, including synchronous blinks and eye closure, blurred vision, foreign body sensation over cornea or eyeball, burning or hot sensation over facial skin, and erythema or pruritus over eyelid, by performing a human trial on patients with lagophthalmos.

NCT ID: NCT03612167 Suspended - Clinical trials for Subjective Cognitive Complaints

Constructing A Model of Health Promotion and Active Aging for Community-Dwelling Older Adults

Start date: March 1, 2013
Phase: N/A
Study type: Interventional

Cognitive intervention for people with subjective cognitive complaints can be categorized into cognitive training, cognitive rehabilitation, psychoeducation, lifestyle intervention, etc. Literature have suggested multicomponent cognitive interventions can have better outcomes. However, studies to support this proposition are still limited. Few studies have also examined the influences of cognitive intervention on functional performance. This study was to examine the effectiveness of a multicomponent cognitive intervention for community-dwelling elderly with subjective cognitive complaints.

NCT ID: NCT03229031 Suspended - Clinical trials for Spinal Cord Injuries

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury

Start date: March 7, 2018
Phase: Phase 3
Study type: Interventional

To demonstrate the superior effect of ES135 combined with spinal cord repairing surgery, compared to a placebo control with spinal cord repairing surgery, on post-surgery motor function recovery as measured by the changes from baseline of ISNCSCI Motor Scores in subjects

NCT ID: NCT03002103 Suspended - Clinical trials for Triple-Negative Breast Cancer

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Start date: November 23, 2016
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, open-label, randomized, and controlled trial to test the superiority of EndoTAG®-1 in combination with paclitaxel and gemcitabine versus paclitaxel in combination with gemcitabine. An independent data safety monitoring board (DSMB) will be established to decide on the recommended dose (RD) of EndoTAG®-1, paclitaxel and gemcitabine to be used throughout the trial and to monitor the patients' safety and treatment efficacy data